XPS™ approved in Canada

XVIVO Perfusion has obtained approval for the XPS™ (Xvivo Perfusion System) in
Canada. This enables clinical use of the XPS™ in Canada.
Health Canada has approved the XPS™ for clinical use in Canada. With its
integrated Hamilton C2 ventilator and MAQUET CardioHelp centrifugal pump, the
XPS™ is the most flexible and complete platform on the market for EVLP (Ex Vivo
Lung Perfusion), and it gives the transplant team full control over the entire
process. The design of the XPS™ means that X-rays and automatic measurements of
oxygen and pH can be carried out while EVLP evaluation is ongoing. The XPS™ has
a user-friendly graphic interface with touchscreen functionality and data
capture of the lung’s values during the entire EVLP procedure. This provides the
basis for analysis and evaluation before a final clinical decision.

XVIVO Perfusion’s XPS™ and STEEN Solution™ are the only approved products in the
USA for evaluation of marginal lungs before transplantation. The XPS™ and STEEN
Solution™ are also CE marked in Europe and approved by the TGA for clinical use
in Australia. Leading clinics in the USA and Europe have obtained good clinical
results when using XPS™.

“We are delighted that the XPS™ is also now available for clinical lung
transplantation in Canada, as this means that the XPS™ has now been approved in
all the major markets in the world,” says Magnus Nilsson, CEO of XVIVO
Perfusion.

November 26, 2015
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on November 26 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com